Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apremilast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C known ✓ | Q08493 | 19/20 | 1.00 |
| ▸ | PDE4A known ✓ | P27815 | 13/20 | 1.00 |
| ▸ | PDE4D known ✓ | Q08499 | 13/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apremilast SCHEMBL302992 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29393225 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29446192 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29392757 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL29350625 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL3135372 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL15869338 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL7135116 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL15869341 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Apremilast SCHEMBL25247853 | 0.99 | PDE4B (0.98) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250366785-A1 | METHODS FOR PROCESSING, ENRICHMENT, DELIVERY, FORMULATION, AND UPTAKE FOR SUPPLEMENTS AND PHARMACEUTICALS | VAN DE CASTEELE RUSSELL (US) | 2025-12-04 | — | — | US | claimed |
| EP-3702347-B1 | PROCESSES FOR THE PREPARATION OF (S)-1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHANESULFONYLETHYLAMINE | AMGEN EUROPE GMBH (CH) | 2023-11-08 | — | — | EP | claimed |
| CN-114269336-A | Combination therapy comprising apremilast and a TYK2 inhibitor | 细胞基因公司 | 2022-04-01 | — | — | CN | claimed |
| CN-114206333-A | Combination therapy comprising apremilast and a TYK2 inhibitor | 细胞基因公司 | 2022-03-18 | — | — | CN | claimed |
| EP-2555769-B1 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | AMGEN EUROPE GMBH (CH) | 2022-01-12 | — | — | EP | claimed |
| US-11040024-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | AMGEN INC. (US) | 2021-06-22 | — | — | US | claimed |
| EP-3320902-B1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | AMGEN EUROPE GMBH (CH) | 2021-02-17 | — | — | EP | claimed |
| US-10919855-B2 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | UNICHEM LABORATORIES LTD (IN) | 2021-02-16 | — | — | US | claimed |
| US-20200368202-A1 | METHODS FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION USING DOSAGE TITRATION OF APREMILAST | CELGENE CORPORATION | 2020-11-26 | — | — | US | claimed |
| CN-111821297-A | Use of isoindoline derivatives for the treatment of immunoglobulin E (IgE) -mediated diseases | 天津合美医药科技有限公司 | 2020-10-27 | — | — | CN | claimed |
| US-20060183788-A1 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION | 2006-08-17 | — | — | US | claimed |
| US-20060148882-A1 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation | ZELDIS JEROME B | 2006-07-06 | — | — | US | claimed |
| WO-2006065814-A1 | COMPOSITIONS COMPRISING PDE4 MODULATORS AND THEIR USE FOR THE TREATMENT OR PREVENTION OF AIRWAY INFLAMMATION | CELGENE CORPORATION (US) | 2006-06-22 | — | — | WO | claimed |
| US-20050267196-A1 | Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants | AMGEN INC. | 2005-12-01 | — | — | US | claimed |
| US-6962940-B2 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | CELGENE CORPORATION (US) | 2005-11-08 | — | — | US | claimed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | claimed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003080048-A1 | (-)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | PDE4B 6/4885PDE4C 8/4885PDE4A 1/4885 |
| US-11040024-B2 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | PDE4A, PDE2A, PDE4B | PDE4B 3/4885PDE4C 7/4885PDE4A 1/4885 |
| US-20060183788-A1 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CHRM3, CHRM1, CHRM2 | PDE4B 63/4885PDE4C 64/4885PDE4A 35/4885 |
| US-20200368202-A1 | METHODS FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION USING DOSAGE TITRATION OF APREMILAST | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | IL4, PTGER4, PDE4A | PDE4B 7/4885PDE4C 11/4885PDE4A 3/4885 |
| US-20060148882-A1 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4C 6/4885PDE4A 1/4885 |
| US-10919855-B2 | Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide | DMPK, BCKDK, MYLK | PDE4B 905/4885PDE4C 1639/4885PDE4A 1215/4885 |
| US-20050267196-A1 | Reducing tumor necrosis factor; phosphodiesterase inhibitor; anticancer agents; antidepressants; antiinflammatory agents; skin dsorders; antidepressants | PDE4A, TNF, PDE4B | PDE4B 3/4885PDE4C 6/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.